title: Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients.
abstract: BACKGROUND
  Prescription opioid dependence is increasing, but treatment outcomes with office-based buprenorphine/naloxone among these patients have not been described.
  
  
  METHODS
  We compared demographic, clinical characteristics and treatment outcomes among 200 patients evaluated for entry into a trial of primary care office-based buprenorphine/naloxone treatment stratifying on those who reported exclusive heroin use (n = 124), heroin and prescription opioid use (n = 47), or only prescription opioid use (n = 29).
  
  
  RESULTS
  Compared to heroin-only patients, prescription-opioid-only patients were younger, had fewer years of opioid use, and less drug treatment history. They were also more likely to be white, earned more income, and were less likely to have Hepatitis C antibodies. Prescription-opioid-only patients were more likely to complete treatment (59% vs. 30%), remained in treatment longer (21.0 vs. 14.2 weeks), and had a higher percent of opioid-negative urine samples than heroin only patients (56.3% vs. 39.8%), all p values < .05. Patients who used both heroin and prescription opioids had outcomes that were intermediate between heroin-only and prescription-opioid-only patients.
  
  
  CONCLUSIONS
  Individuals dependent on prescription opioids have an improved treatment response to buprenorphine/naloxone maintenance in an office-based setting compared to those who exclusively or episodically use heroin.
authors: Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06519, USA. brent.moore@yale.edu
authors: Brent A
authors: BA
authors: Moore
authors: David A
authors: DA
authors: Fiellin
authors: Declan T
authors: DT
authors: Barry
authors: Lynn E
authors: LE
authors: Sullivan
authors: Marek C
authors: MC
authors: Chawarski
authors: Patrick G
authors: PG
authors: O'Connor
authors: Richard S
authors: RS
authors: Schottenfeld
mesh_terms: D000328:Adult; D000701:Analgesics, Opioid / Q000008:administration & dosage; D002047:Buprenorphine / Q000627:therapeutic use*; D005260:Female; D003932:Heroin / Q000008:administration & dosage; D006556:Heroin Dependence / Q000188:drug therapy* / Q000453:epidemiology*; D006801:Humans; D008297:Male; D009819:Office Visits; D009293:Opioid-Related Disorders / Q000188:drug therapy / Q000453:epidemiology; D011320:Primary Health Care / Q000379:methods
chemical_list: D000701:Analgesics, Opioid; D002047:Buprenorphine; D003932:Heroin